Infectious Optimism following the 10th International Oncolytic Virus Meeting

Matthew J. Atherton; Laura Evgin; Brian A. Keller; Mira M. Shenouda; Kyle B. Stephenson; Richard G. Vile; John C. Bell; David H. Evans; Brian D. Lichty

Molecular Therapy: Oncolytics (Dec 2017)

Infectious Optimism following the 10th International Oncolytic Virus Meeting

Matthew J. Atherton,
Laura Evgin,
Brian A. Keller,
Mira M. Shenouda,
Kyle B. Stephenson,
Richard G. Vile,
John C. Bell,
David H. Evans,
Brian D. Lichty

Affiliations

Matthew J. Atherton: McMaster Immunology Research Centre, McMaster University, Hamilton, ON L8S 4K1, Canada
Laura Evgin: Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA
Brian A. Keller: Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON K1Y 4E9, Canada
Mira M. Shenouda: Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB T6G 2E1, Canada
Kyle B. Stephenson: Turnstone Biologics, Ottawa, ON K1S 3V5, Canada
Richard G. Vile: Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA
John C. Bell: Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON K1Y 4E9, Canada; Turnstone Biologics, Ottawa, ON K1S 3V5, Canada
David H. Evans: Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB T6G 2E1, Canada
Brian D. Lichty: McMaster Immunology Research Centre, McMaster University, Hamilton, ON L8S 4K1, Canada; Turnstone Biologics, Ottawa, ON K1S 3V5, Canada; Corresponding author: Brian D. Lichty, McMaster Immunology Research Centre, McMaster University, Hamilton, ON L8S 4K1, Canada.

Journal volume & issue: Vol. 7
pp. 12 – 16

Abstract

Read online

The 10th International Conference on Replicating Oncolytic Virus Therapeutics was held in Vancouver, Canada from October 1–4, 2016. The agenda for the meeting comprised lectures from several streams within the field of oncolytic viral therapeutics. Exploring the strengthening relationship among oncolytic viruses, cancer immunology, and immunotherapy; gaining an understanding for effective therapeutic delivery routes; and learning of exciting results from translational studies all featured prominently among areas discussed. As the field matures, commercialization and patient-centered research have become important avenues for growth; however, an abundance of high quality laboratory-based science continues to be performed in order to optimize future therapeutic approaches. Here, we summarize the latest innovations presented at this meeting. Keywords: oncolytic virus, cancer immunotherapy, clinical trials

Published in Molecular Therapy: Oncolytics

ISSN: 2372-7705 (Online)
Publisher: Elsevier
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.cell.com/molecular-therapy-family/oncolytics/latest-content

About the journal